FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1653750710> ?p ?o ?g. }

• W1653750710 endingPage "22" @default.
• W1653750710 startingPage "17" @default.
• W1653750710 abstract "Objectives Predictive factors for efficacy of bevacizumab in advanced ovarian cancer have remained elusive. We investigated ascites both as a prognostic factor and as a predictor of efficacy for bevacizumab. Methods Using data from GOG 0218, patients receiving cytotoxic therapy plus concurrent and maintenance bevacizumab were compared to those receiving cytotoxic therapy plus placebo. The presence of ascites was determined prospectively. Chi-square and Wilcoxon–Mann–Whitney tests compared baseline variables between subgroups. Survival was estimated by Kaplan–Meier method, and Cox proportional hazard models were used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on survival. Results Treatment arms were balanced with respect to ascites and other prognostic factors. Overall, 886 (80%) women had ascites, 221 (20%) did not. Those with ascites were more likely to have: poorer performance status (p < 0.001); serous histology (p = 0.012); higher baseline CA125 (p < 0.001); and suboptimal cytoreduction (p = 0.004). In multivariate survival analysis, ascites was prognostic of poor OS (Adjusted HR 1.22, 95% CI 1.00–1.48, p = 0.045), but not PFS. In predictive analysis, patients without ascites treated with bevacizumab had no significant improvement in either PFS (AHR 0.81, 95% CI 0.59–1.10, p = 0.18) or OS (AHR 0.94, 95% CI 0.65–1.36, p = 0.76). Patients with ascites treated with bevacizumab had significantly improved PFS (AHR 0.71, 95% CI 0.62–0.81, p < 0.001) and OS (AHR 0.82, 95% CI 0.70–0.96, p = 0.014). Conclusions Ascites in women with advanced ovarian cancer is prognostic of poor overall survival. Ascites may predict the population of women more likely to derive long-term benefit from bevacizumab." @default.
• W1653750710 created "2016-06-24" @default.
• W1653750710 creator A5012406980 @default.
• W1653750710 creator A5012623536 @default.
• W1653750710 creator A5014611244 @default.
• W1653750710 creator A5046031005 @default.
• W1653750710 creator A5053990407 @default.
• W1653750710 creator A5057221032 @default.
• W1653750710 creator A5058244284 @default.
• W1653750710 creator A5060497385 @default.
• W1653750710 creator A5060972300 @default.
• W1653750710 creator A5065411475 @default.
• W1653750710 creator A5076850754 @default.
• W1653750710 date "2015-10-01" @default.
• W1653750710 modified "2023-09-29" @default.
• W1653750710 title "Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study" @default.
• W1653750710 cites W1520642707 @default.
• W1653750710 cites W1589068001 @default.
• W1653750710 cites W1658618454 @default.
• W1653750710 cites W1827936231 @default.
• W1653750710 cites W1972978214 @default.
• W1653750710 cites W1974122093 @default.
• W1653750710 cites W1985503139 @default.
• W1653750710 cites W1991236190 @default.
• W1653750710 cites W1995637683 @default.
• W1653750710 cites W2013264198 @default.
• W1653750710 cites W2018889021 @default.
• W1653750710 cites W2023907325 @default.
• W1653750710 cites W2031648200 @default.
• W1653750710 cites W2096521047 @default.
• W1653750710 cites W2099499481 @default.
• W1653750710 cites W2105007540 @default.
• W1653750710 cites W2105651363 @default.
• W1653750710 cites W2113122060 @default.
• W1653750710 cites W2113545156 @default.
• W1653750710 cites W2132889339 @default.
• W1653750710 cites W2135947389 @default.
• W1653750710 cites W2142874979 @default.
• W1653750710 cites W2154885792 @default.
• W1653750710 cites W2170928115 @default.
• W1653750710 cites W2171658624 @default.
• W1653750710 cites W4293241248 @default.
• W1653750710 doi "https://doi.org/10.1016/j.ygyno.2015.07.103" @default.
• W1653750710 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4600605" @default.
• W1653750710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26216729" @default.
• W1653750710 hasPublicationYear "2015" @default.
• W1653750710 type Work @default.
• W1653750710 sameAs 1653750710 @default.
• W1653750710 citedByCount "67" @default.
• W1653750710 countsByYear W16537507102015 @default.
• W1653750710 countsByYear W16537507102016 @default.
• W1653750710 countsByYear W16537507102017 @default.
• W1653750710 countsByYear W16537507102018 @default.
• W1653750710 countsByYear W16537507102019 @default.
• W1653750710 countsByYear W16537507102020 @default.
• W1653750710 countsByYear W16537507102021 @default.
• W1653750710 countsByYear W16537507102022 @default.
• W1653750710 countsByYear W16537507102023 @default.
• W1653750710 crossrefType "journal-article" @default.
• W1653750710 hasAuthorship W1653750710A5012406980 @default.
• W1653750710 hasAuthorship W1653750710A5012623536 @default.
• W1653750710 hasAuthorship W1653750710A5014611244 @default.
• W1653750710 hasAuthorship W1653750710A5046031005 @default.
• W1653750710 hasAuthorship W1653750710A5053990407 @default.
• W1653750710 hasAuthorship W1653750710A5057221032 @default.
• W1653750710 hasAuthorship W1653750710A5058244284 @default.
• W1653750710 hasAuthorship W1653750710A5060497385 @default.
• W1653750710 hasAuthorship W1653750710A5060972300 @default.
• W1653750710 hasAuthorship W1653750710A5065411475 @default.
• W1653750710 hasAuthorship W1653750710A5076850754 @default.
• W1653750710 hasBestOaLocation W16537507102 @default.
• W1653750710 hasConcept C121608353 @default.
• W1653750710 hasConcept C126322002 @default.
• W1653750710 hasConcept C141071460 @default.
• W1653750710 hasConcept C143998085 @default.
• W1653750710 hasConcept C207103383 @default.
• W1653750710 hasConcept C2775883341 @default.
• W1653750710 hasConcept C2776694085 @default.
• W1653750710 hasConcept C2777802072 @default.
• W1653750710 hasConcept C2780427987 @default.
• W1653750710 hasConcept C2780496750 @default.
• W1653750710 hasConcept C44249647 @default.
• W1653750710 hasConcept C50382708 @default.
• W1653750710 hasConcept C71924100 @default.
• W1653750710 hasConcept C90924648 @default.
• W1653750710 hasConceptScore W1653750710C121608353 @default.
• W1653750710 hasConceptScore W1653750710C126322002 @default.
• W1653750710 hasConceptScore W1653750710C141071460 @default.
• W1653750710 hasConceptScore W1653750710C143998085 @default.
• W1653750710 hasConceptScore W1653750710C207103383 @default.
• W1653750710 hasConceptScore W1653750710C2775883341 @default.
• W1653750710 hasConceptScore W1653750710C2776694085 @default.
• W1653750710 hasConceptScore W1653750710C2777802072 @default.
• W1653750710 hasConceptScore W1653750710C2780427987 @default.
• W1653750710 hasConceptScore W1653750710C2780496750 @default.
• W1653750710 hasConceptScore W1653750710C44249647 @default.
• W1653750710 hasConceptScore W1653750710C50382708 @default.
• W1653750710 hasConceptScore W1653750710C71924100 @default.

• next